MENU
+Compare
CRVS
Stock ticker: NASDAQ
AS OF
Sep 17, 12:45 PM (EDT)
Price
$5.98
Change
+$0.24 (+4.18%)
Capitalization
427.71M

CRVS Corvus Pharmaceuticals Forecast, Technical & Fundamental Analysis

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function... Show more

CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CRVS with price predictions
Sep 16, 2025

CRVS saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for CRVS moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 53 similar instances where the indicator exited the overbought zone. In of the 53 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CRVS moved out of overbought territory on September 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for CRVS turned negative on September 12, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CRVS broke above its upper Bollinger Band on September 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 13, 2025. You may want to consider a long position or call options on CRVS as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for CRVS moved above the 200-day moving average on September 10, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRVS advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 137 cases where CRVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.330) is normal, around the industry mean (20.568). P/E Ratio (0.000) is within average values for comparable stocks, (53.310). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.111). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (333.018).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CRVS is expected to report earnings to rise 31.70% to -13 cents per share on October 30

Corvus Pharmaceuticals CRVS Stock Earnings Reports
Q3'25
Est.
$-0.13
Q2'25
Beat
by $0.03
Q1'25
Missed
by $0.01
Q4'24
Missed
by $0.06
Q3'24
Missed
by $0.49
The last earnings report on August 07 showed earnings per share of -10 cents, beating the estimate of -12 cents. With 74.54K shares outstanding, the current market capitalization sits at 427.71M.
A.I. Advisor
published General Information

General Information

a provider of anticancer immuno-oncology drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
863 Mitten Road
Phone
+1 650 900-4520
Employees
28
Web
https://www.corvuspharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SICWX80.480.02
+0.02%
Touchstone Large Cap Focused Y
TPIIX15.67N/A
N/A
Timothy Plan International I
NWCAX62.05-0.19
-0.31%
Nuveen Winslow Large-Cap Growth ESG A
PMVFX26.62-0.10
-0.37%
PGIM Quant Solutions Mid-Cap Val R4
GQEPX21.48-0.09
-0.42%
GQG Partners US Select Quality Eq Inv

CRVS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-2.38%
SYRE - CRVS
42%
Loosely correlated
-0.13%
TERN - CRVS
39%
Loosely correlated
+2.38%
IPSC - CRVS
39%
Loosely correlated
-1.49%
RZLT - CRVS
36%
Loosely correlated
+3.35%
DNLI - CRVS
34%
Loosely correlated
+0.76%
More